MacroGenics Inc (MGNX)

NASDAQ
5.10
+0.55(+12.09%)
After Hours
5.19
+0.09(+1.76%)
- Real-time Data
  • Volume:
    1,291,328
  • Day's Range:
    4.41 - 5.27
  • 52 wk Range:
    2.13 - 28.09

MGNX Overview

Prev. Close
4.55
Day's Range
4.41-5.27
Revenue
66.92M
Open
4.6
52 wk Range
2.13-28.09
EPS
-3.57
Volume
1,291,328
Market Cap
313.44M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,321,950
P/E Ratio
-1.28
Beta
-
1-Year Change
-79.11%
Shares Outstanding
61,458,790
Next Earnings Date
Nov 09, 2022
What is your sentiment on MacroGenics Inc?
or
Market is currently closed. Voting is open during market hours.

MacroGenics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

MacroGenics Inc Analysis

MacroGenics Inc Company Profile

MacroGenics Inc Company Profile

Employees
427

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuySell
Technical IndicatorsSellStrong BuyStrong BuyStrong BuyStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Sell